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Myostatin (Mstn) is an inhibitor of myogenesis, regulating the number and size of skeletal myocytes. In
addition to its myogenic regulatory function, Mstn plays important roles in the development of adipose
tissues and in metabolism. In the present study, an Mstn knockout rat model was generated using the
zinc ﬁnger nuclease (ZFN) technique in order to further investigate the function and mechanism of Mstn
in metabolism. The knockout possesses a frame shift mutation resulting in an early termination codon
and a truncated peptide of 109 amino acids rather than the full 376 amino acids. The absence of
detectable mRNA conﬁrmed successful knockout of Mstn. Relative to wild-type (WT) littermates,
Knockout (KO) rats exhibited signiﬁcantly greater body weight, body circumference, and muscle mass.
However, no signiﬁcant differences in grip force was observed, indicating that Mstn deletion results in
greater muscle mass but not greater muscle ﬁber strength. Additionally, KO rats were found to possess
less body fat relative to WT littermates, which is consistent with previous studies in mice and cattle. The
aforementioned results indicate that Mstn knockout increases muscle mass while decreasing fat content,
leading to observed increases in body weight and body circumference. The Mstn knockout rat model
provides a novel means to study the role of Mstn in metabolism and Mstn-related muscle hypertrophy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Myostatin (Mstn), also known as growth and differentiation
factor 8 (GDF-8), is a member of the secreted transforming growth
factor-b (TGF-b) superfamily of secreted growth factors and is a
negative regulator of skeletal muscle development [1]. In mam-
mals, Mstn is primarily expressed in skeletal muscle [2], although
weak expression in other tissues such as adipose [2], heart [3],
mammary gland [4], spleen [5], and placenta [6] have also been
observed. The fact that the myostatin protein sequence is highly
conserved from rodents to human suggests conservation ofal Science, Chinese Academy
eijing 100021, China.
ince for Zoonosis Prevention
of Military Medical Sciences,
cnilas.org (W. Yong).
r Inc. This is an open access articlefunction [7,8]. Mstn knockout mice exhibit dramatically increased
muscle mass from an increased number of muscle ﬁbers (hyper-
plasia) formed during development and increased ﬁber size (hy-
pertrophy) in adulthood [2,9]. Likewise, naturally occurring Mstn
gene mutations generate the similar phenotype of muscular hy-
pertrophy in many different mammalian species including cattle,
sheep, dogs, and humans [10]. Mstn regulates muscle homeostasis,
as myostatin upregulation is observed in skeletal muscle atrophy
and in the pathogenesis of muscle wasting during cachexia asso-
ciated with different diseases (i.e. cancer, chronic heart failure,
AIDS, sarcopenia) [1,11]. What’s more, the use of antisense RNA,
neutralizing antibodies, or chemical inhibitors against myostatin
can improve this observed muscle wasting in animal models of
disease [1,12e17].
The humanMstn gene is located on chromosome 2 (2q32.2) and
is ﬂanked by a number of binding sites and response elements for
transcription factors and hormones, including MyoD (a myogenic
regulatory factor), glucocorticoid, and androgen [18,19], suggestingunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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addition to regulating muscle development and homeostasis,
myostatin also exerts effects on adipocyte differentiation, as well as
adipose accumulation and turnover. Myostatin has been shown to
inhibit or stimulate adipogenesis in various cell culture systems
[20], but the reduced expression of the adipogenic markers, such as
CCAAT/enhancer binding protein a and peroxisome proliferator-
activated receptor g [21], as well as the reduced fat accumulation
in mstn-deﬁcient mice [21e23], suggest myostatin promotes adi-
pogenesis in vivo. Furthermore, mstn deﬁciency can prevent high-
fat diet-induced obesity through enhanced fatty acid oxidation
and brown adipose formation in white adipose tissue [24]. Finally,
myostatin has been found to reduce insulin sensitivity in response
to neuronal stimulation of brown adipose tissue or via degradation
of insulin receptor substrate 1 in response to high caloric intake
[25,26]. Hence, myostatin appears to play an important role in
metabolic pathways not directly related to muscle growth.
Multiple studies have implicated myostatin as a potential target
for many human diseases. Most of these studies were performed
using mouse models. Given the difﬁculty of modifying its largely
intractable genome, few studies were carried out in rat, another
welleestablished model for the genetic dissection of human dis-
ease. From an evolutionary point of view, rats are more genetically
similar to humans and possess several genes not found in mice,
including genes involved in immunity, chemosensation, detoxiﬁ-
cation and proteolysis. For proteolysis plays a regulatory function in
myostatin signaling [27,28] and myostatin expression has an in-
ﬂuence on cytokine secretion within the immune system [5], the
activity of myostatin could be quite different between deﬁcient rats
and deﬁcient mice. In fact, Mendias et al. recently reported that the
muscle and tendon phenotype of Mstn-null rats established using
the zinc ﬁnger nuclease (ZFN) technique was markedly different
from that ofMstn-null mice, which have impaired contractility and
pathological changes to ﬁbers and their extracellular matrix [29].
While that study demonstrated some important distinctions be-
tween the mouse and rat models, it examined neither effects on fat
content nor sex-speciﬁc phenotypes in Mstn-null rats.
The present study characterizes a novel Mstn-knockout rat
model developed using the ZFN technique, examining the muscle
mass and fat contents, to provide a foundation for further studies of
Mstn function.2. Materials and methods
2.1. Animals
All experimental protocols were reviewed and approved by the
ethics committee Institute of Laboratory Animal Science of Peking
Union Medical College. Male and female Sprague Dawley rats were
purchased fromHuafukang Biotech (Beijing, China) andmaintained
in the animal facility of the Institute of Laboratory Animal Science
of Peking Union Medical College. Rats were housed with 12/12-h
dark/light cycle and given free access to food and water. Mea-
surements were taken to minimize pain and discomfort of animals
during all procedures.3. Materials
ClaI enzyme, Taq enzyme, dNTP mixture, polymerase chain re-
action (PCR) buffer, SYBR Premix Ex TaqII, and PrimeScript 1st
Strand cDNA Synthesis Kit were purchased from Takara Co., Ltd
(Dalian, China). Diethylpyrocarbonate (DEPC) H2O and TRIzol re-
agent were purchased from Invitrogen (Shanghai, China). Protein-
ase K and agarose were purchased from Sigma (Shanghai, China).4. Methods
4.1. ZFN construct design and in vitro transcription
ZFN constructs were co-designed by Sigma-Aldrich (MO, USA).
The methods have been described in detail elsewhere [30e32]. In
brief, ZFNs were designed to target the genomic region around rat
mstn exon 1 and each were tested for their efﬁciency in knocking
out gene expression in the rat cell line C6. Cells were transfected
with the ZFNs and harvested the following day. DNA and RNAwere
isolated and Surveyor nuclease cleavage analysis was performed
according to the manufacturer’s protocol (Transgenomic, NE, USA).
4.2. Creation of Mstn KO rat and sequencing conﬁrmation
Embryos and microinjection were performed as previously
described [33]. Genomic DNA from the ZFN-modiﬁed founder animal
was sequenced to conﬁrm the presence of the ZFN-induced mutation.
In brief, genomic DNA was extracted from the tails of newborn (10 d)
rats using the salting-out method (ref). PCR was performed to amplify
the Mstn sequence with the primers 50-GGCATGGTAAT-
GATTGTTTCCGTG-30 (forward) and 50-TTTACCTGTTTGTGCT-
GATTGCTGC-30 (reverse). Conditions for PCR ampliﬁcationwere set as:
94 C pre-denaturation for 5 min, 94 C denaturation for 30 s, 60 C
annealing for 30 s, 72 C elongation for 1min, 35 cycles, and 72 C ﬁnal
elongation for 10 min. Conﬁrmed ZFN-mediated Mstn knockout F1
founder rats were backcrossed to WT Sprague Dawley rats. Hetero-
zygous rats were crossed to generate Mstn homozygous KO rats. To
reduce the probability of nonspeciﬁc ZFN-mediated deletion effects, F1
rats were backcrossedwithWT Sprague Dawley rats for 5 generations.
4.3. Mstn mutant genotyping
Genomic DNA was extracted from the tails newborn (10 d) rats.
Primers and PCR conditions were employed as above. PCR products
were digested by ClaI restriction endonuclease at 30 C overnight
and fractioned on a 2% agarose gel.
4.4. RNA extraction and real-time PCR
Rats were anesthetized with 0.6% sodium pentobarbital (0.8 ml/
100 g) and the trapezius dorsi muscle tissues were collected for
RNA extraction using TRIzol. Reverse transcription (RT) was per-
formed on total RNA (500 ng) and the cDNA products were used as
a template for quantitative real-time PCR (qRT-PCR) (Applied Bio-
systems 7500, ABI, CA, USA). SYBR green was used as a ﬂuorescent
label and primers speciﬁcity was tested by applying the melting
curve cycle. qRT-PCR conditions were as follows: 95 C pre-
denaturation for 5 min, 95 C denaturation for 30 s, 60 C anneal-
ing for 30 s, 72 C elongation for 30 s, 40 cycles, followed by ﬁnal
denaturation at 95 C for 15 s and ﬁnal elongation at 60 C for 1min
b-actin was used as an internal control and the expression of Mstn
was represented by 2DDCt, where DDCt¼ (CtmutantMstne Ctmutant-b-
actin) e (Ctwild type-Mstn e Ctwild type-b-actin).
4.5. Primer sequences for Mstn
Forward: 50- GATCGATCAGTACGACGTCCA-30
Reverse:50-GAAAGTCAGACTCGGTAGGC-304.6. Primer sequences for b-actin
Forward: 50- CACCCGCGAGTACAACCTTC-30
Reverse:50-CCCATACCCACCATCACACC-30
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Male (Mstn þ/þ (n ¼ 7), Mstn þ/ (n ¼ 5), and Mstn / (n ¼ 6))
and female (Mstn þ/þ (n¼ 7),Mstn þ/ (n¼ 6), andMstn / (n¼ 6))
rats were selected and weighed weekly from the 2nd to the 17 th
week after birth. Body weights were compared via 2-way analysis
of variance (ANOVA) and statistical signiﬁcance was deﬁned as
P < 0.05.
4.8. Measuring muscle weight
Male rats aged 5-, and 20-weeks-old (n ¼ 3 per group) were
anesthetized with 0.6% sodium pentobarbital (0.8 ml/100 g). The
trapezius dorsi muscle was collected, weighed, and photographed
alongside. A Vernier caliper was used to determine muscle thick-
ness. For inconvenient measurement to muscle volume, we adop-
ted an alternative method to measure muscle weight. ImageJ
software was used to calculate the area (cm2) of the muscle. Muscle
weight per unit area (g/cm2) was calculated by dividing the mass of
the muscle (g) by the area of muscle (cm2).
4.9. Measuring grip strength
Male rats aged 5-months-old, (n ¼ 3 per genotype) were
selected and measured for their grip strength using an YLS-13A
dynamometer (Jinan Yiyan Technology and Development Co., Ltd.,
Shandong, China). During measurement, an experimenter grabbed
the middle part of the rat tail and horizontally pulled it back with
even force, until the rat withdrew its paws from the dynamometer.
The dynamometer would automatically record the maximum grip
strength in Newtons. The grip strength of each rat was averaged
with 6 attempts.
4.10. MRI imaging
Male rats aged 5-months-old, (n ¼ 3 per genotype) were anes-
thetized with 0.6% sodium pentobarbital (0.8 ml/100 g) and their
fat content was assessed using an Agilent 7.0T magnetic resonance
imaging (MRI) system for animal imaging (Agilent, 7T/160/AS,
USA). The parameters of MRI were set as follows: TR/TE 230 ms/
16 ms; FOV 70 mm  45 mm; slice thickness 1 mm; interslice gap
1 mm; 4 slices; matrix 256  256; scanning time 3 min 55 s. The
parameters for axial scanning were set as follows: FOV
40 mm  45 mm. IRW software (Inveon Research Workplace) was
used to calculate the fat content in each slice, which was combined
to determine the whole-body fat content.
4.11. Statistical analysis
Data are presented as mean ± standard deviation (SD). Two-way
analysis of variance (ANOVA) was performed for multi-group
comparisons, while a t-test was performed for intergroup com-
parison. Statistical signiﬁcance was deﬁned as P < 0.05.
5. Results
5.1. Construction and identiﬁcation of Mstn knockout rats
A ZFN construct engineered to target bp 277e281 of rat Mstn
was used for the rat embryo injection (Fig. 1A). After multiple trials,
3 mutant Mstn rats were successfully created (Fig. 1B). Gene
sequencing results indicated that the #6 ZFN-targeted sequence
was changed from GATCA to AGTC, resulting in a frame shift mu-
tation within the open reading frame (Fig. 1C). Comparison to the
wild-type gene sequence revealed that the frame shift mutationgenerated an early termination codon, resulting in a truncated 109
amino acid peptides rather than the full-length 376 amino acid
MSTN (Fig. 1C). Another effect of the #6 ZFN-mediated Mstn mu-
tation was the removal of a ClaI restriction site (ATCGAT) (Fig. 1A).
Thus, Mstn þ/þ, Mstn ± and Mstn / could be distinguished by PCR
ampliﬁcation followed by ClaI digestion. After agarose gel electro-
phoresis, fragment number was used to identify wild-type (2),Mstn
homozygous knockout (1), and heterozygous rats (3) (Fig. 1D). To
further verify functionalMstn knockout, qRT-PCR was performed to
measure the expression ofMstnmRNA inMstn þ/þ,Mstn ± andMstn
/. In homozygous knockout rats, Mstn expression was
18.92± 3.33% (P < 0.001) of the wild-type expression level (Fig. 1E).
This indicated that the open reading frame shift mutation could still
be transcribed into mRNA, but the stability of mRNA might be
affected.
5.2. The inﬂuence of Mstn on rat weight and size
Because Mstn is a negative regulatory factor of muscle growth,
rats with Mstn deletion were expected to demonstrate an increase
in muscle mass. To test this, the body weights of male and female
Mstn þ/þ, Mstn ± and Mstn / rats were collected weekly from the
2nd to the 17 th week after birth. The results revealed that relative
to male WT rats, the weights of maleMstn / rats were noticeably
higher at week 4, gaining signiﬁcance difference at week 8
(272.92 ± 1.97 g vs. 334.45 ± 18.21 g, P < 0.05). By the end of week
17, the difference was even greater (463.55 ± 6.58 g vs.
591.77 ± 36.31 g, P < 0.001) (Fig. 2A). While male Mstn ± rats
demonstrated body weights slightly higher than WT beginning at
week 17, the differences were never statistical signiﬁcant differ-
ences. After 17 weeks of feeding, the difference in the size of male
Mstn / rats compared to Mstn (þ/þ) rats was apparent (Fig. 2C).
Interestingly, the body weights of female Mstn / rats were only
slightly higher than that of WT rats, with no statistical signiﬁcant
differences observed (P > 0.05) (Fig. 2B). The disparate results be-
tween male and female rats suggest that Mstn may function in a
sex-speciﬁc manner. Because Mstn deletion did not signiﬁcantly
inﬂuence the weight and size of female rats, only male rats were
utilized for further experiments.
5.3. The inﬂuence of Mstn on muscle development
Because Mstn negatively regulates muscle growth, muscle
development was compared between WT and Mstn knockout rats.
The abdominal external oblique muscle of 3-, 5-, and 20-week-old
rats were collected, weighed, and measured for size. As predicted,
Mstn / rats in all age groups possessed signiﬁcantly greater
muscle weight/size relative to WT rats (0.885 ± 0.026 g/cm2 vs.
0.678 ± 0.042 g/cm2 (30.59%), P < 0.05; 2.216 ± 0.049 g/cm2 vs.
1.823 ± 0.058 g/cm2 (21.54%), P < 0.01; 4.981 ± 0.451 g/cm2 vs.
4.150 ± 0.466 g/cm2 (20.04%), P < 0.01) (Fig. 3A). The thickness of
the back muscle was measured for rats aged 20 weeks, revealing
that Mstn / rats possessed abdominal external oblique muscle
thickness signiﬁcantly greater than WT rats (0.662 ± 0.008 mm vs.
0.502 ± 0.009mm, P < 0.0001) (Fig. 3B). Given the visible difference
in forelimb size (Fig. 3C), a dynamometer was used to measure the
grip strength of 20-week-old Mstn / and WT rats. Despite the
larger forelimb musculature, the average grip strengths ofMstn /
and WT rats were not signiﬁcantly different (Fig. 3D).
5.4. The inﬂuence of Mstn on rat fat content
To explore the function of Mstn in adipose generation and
metabolism, differences in fat distribution were measured in 5-
month-old Mstn knockout and WT rats. Relative to WT rats, Mstn
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the abdominal cavity, mesentery, and epididymis (Fig. 4A). MRI-
generated quantitative measurements revealed that the fat con-
tent of Mstn / rats was 45% lower than of WT rats
(14.22300 ± 1.16016 cm3 vs. 25.91007 ± 1.12717 cm3, P < 0.0001)
(Fig 4B, C). Thus Mstn deletion not only enhanced rat muscle
development but also diminished fat content.
6. Discussion
Using the ZFN technique, this study successfully established an
Mstn knockout rat model, inwhich a frame shift mutation in exon 1
of the Mstn gene results in a truncated and non-functional MSTN
protein.
Body weight comparisons revealed that Mstn knockoutFig. 1. Design of Mstn ZFN constructs and veriﬁcation of Mstn knockout. (A) The design o
facilitate FokI endonuclease cleavage at a speciﬁc site within exon 1 of Mstn. The non-homol
early termination codon and a truncated protein of 109 amino acids. The purple line indicat
non-homologous end joining. (B) Sequencing of PCR products obtained from F1 rats: the ar
rats: the products were indistinguishable at 337 bp each. (D) Electrophoresis of PCR products
244 bp and 93 bp. Wild-type rats possessed a clear band at 244 bp,Mstn knockout rats posse
bp band. Lane 1 representsMstn knockout, lane 2 represents heterozygous, and lane 3 repres
of rats. Mean ± SD, N ¼ 3. ***P < 0.001. (For interpretation of the references to colour in thsigniﬁcantly increases the body weights of maleMstn knockout rats
by nearly 20% compared with WT rats at 17 weeks of age. Previous
studies have reported that Mstn naturally mutant animals (cattle,
sheep, and humans) [7,34e39] or artiﬁcially-generated mutant
animals (mice, rats) [29,40] generally demonstrate a 20e40% in-
crease in muscle weights due to muscle hypertrophy or hyperplasia
relative to WT animals. Therefore, the observed differences in
muscle and body size in male Mstn / rats are not very surprising.
Notably, no signiﬁcant differences in body weight were found in
female Mstn / rats, a ﬁnding inconsistent with studies of Mstn
knockout mice, where differences between mutant and WT body
weights were found to be relatively constant irrespective of age or
sex [2,41]. Similarly, both male and female Mstnmutant mice were
characterized as possessing pronounced musculature [40]. This
sex-speciﬁc effect of Mstn on body weight might be a novelf restriction sites on Mstn ZFN constructs: Speciﬁc recognition sites were designed to
ogous recombination repair mechanism induced a frame shift mutation, resulting in an
es the ClaI restriction site (AT CGAT), which was removed during gene knockout. NHEJ:
row indicates the mutation site. (C) Electrophoresis of PCR products obtained from F3
after ClaI digestion: WT PCR product (337 SSbp) predicted digestion products would be
ssed a single band at 337 bp, and heterozygous rats possessed both the 244 bp and 337
ents WT. (E) RT-PCR determination ofMstnmRNA expression in WT andMstn knockout
is ﬁgure legend, the reader is referred to the web version of this article.)
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notworthilyMstn/- mice did not continue to gain weight beyond 6
months of age, and the total body weight of Mstnþ/þ mice were
comparable to those of Mstn/- mice by 9e10 months of age [22],
but to male Mstn / rats, the difference in body weitht seemed to
lifelong. The recent establishment and characterization of another
knockout rat model, produced by the ZFN-mediated deletion of the
splice acceptor of exon 2 of Mstn, did not investigate potential sex-
speciﬁc differences in body weight [29]. It will be interesting to
discover whether such gender differences are present in this model
as well. Several lines of evidence support the idea that Mstn
function is regulated disparately in males and females. Research on
risk factors for sarcopenia among community-dwelling older adults
revealed that while age was associated with sarcopenia in both
genders, malnutrition conferred signiﬁcantly higher odds for sar-
copenia in women [42]. Hormones possibly account on the differ-
ences between two genders, since Mstn is ﬂanked by number of
binding sites for hormones [18,19]. For example, androgens can
induce Mstn signaling in a negative feedback mechanism [18],
perhaps the sex-speciﬁc differences observed are due to the rela-
tive abundance of androgens in males and females. Probably, wild-
type male rats maintain proper muscle homeostasis via AR-
mediated Mstn activation and male Mstn knockout rats developed
a double-muscle phenotype. While in wild-type female rats, other
mechnism not an AR mediated Mstn-dependent manner regulates
the muscle homeostasis,, such that female Mstn knockout rats
would not demonstrate greater body weight or muscle growth.
Further research will be required to determine whether there is
indeed a sex-speciﬁc role for Mstn.
The current study also demonstrated extraordinary muscleFig. 2. The inﬂuence ofMstn deletion on rat weight and size. (A) The inﬂuence of Mstn delet
/ (n ¼ 6) rats were selected and weighed weekly from the 2nd to the 17 th week after birt
(n ¼ 7), Mstn þ/ (n ¼ 6), and Mstn / (n ¼ 6) rats were selected and weighed weekly from
Mstn þ/þ and Mstn / rats at 17-weeks old age. Mean ± SD. *P < 0.05; ***P < 0.001.development in the back and limbs of male ratswithMstn konckout
(data not shown). This was consistent with the results obtained in
other species, which demonstrated a double-muscle phenotype.
Histological staining was utilized in multiple studies to determine
that this phenotype is characterized by muscle hypertrophy or
hyperplasia [8,10]. Previous studies have analyzed the effects of
Mstn on diameter and number of muscle ﬁbers, but no study has
evaluated the overall thickness of individual muscles. In this study,
trapezius dorsi muscles were collected fromwild-type andMstn /
rats, and the weight per unit area were calculated. The results
reveal that Mstn knockout signiﬁcantly increased weight per unit
area and thickness of the musculature. However the bulkier mus-
cles failed to translate into greater strength, as revealed using the
dynamometer. Although the reason for this is unclear, it may be
attributable to anMstn knockout-induced change in the abundance
of mitochondria within the myocytes, further decreasing cell
phosphorylation capacity [43]. Comparable results were demon-
strated in Mstn knockout mice, which possessed greater muscle
mass, but no elevation in maximummuscle tension. In fact, several
measures of strength were lower than that of wild-type mice;
muscles from knockout mice contracted and relaxed faster during a
single twitch, and were more prone to fatigue [44]. Further inves-
tigation revealed that genetic defects ofMstn results in a metabolic
transition within the muscle cells from an aerobic to an anaerobic
condition [43]. These results indicate that although Mstn inhibits
muscle growth, it endows the skeletal muscle with higher oxidative
capacity and fatigue resistance, which requires further
examination.
The present study revealed that Mstn / rats possess signiﬁ-
cantly less fat than WT rats at 5-month old, as determined byion on male rat body weight: littermates ofMstn þ/þ (n ¼ 7),Mstn þ/ (n ¼ 5), and Mstn
h. (B) The inﬂuence of Mstn deletion on female rat body weight: littermates of Mstn þ/þ
the 2nd to the 17 th week after birth. (C) Body size comparison of male littermates of
Fig. 3. The inﬂuence ofMstn on rat muscle development. (A) The weight of trapezius dorsi muscle for rats at different developmental stages. Trapezius dorsi muscles were collected,
measured, and weighed to calculate the weight of muscle per unit area (n ¼ 3 per genotype). (B) Measuring the thickness of trapezius dorsi muscle for 5-month-old rats. Bar ¼ 1 cm.
(C) Representative comparison of forelimbs collected at 5-month-old. (D) Measuring the grip strength of 5-month-old rats (n ¼ 3 per genotype). Measurements for each rat were
collected 6 times. The average was used for statistical analysis. Mean ± SD. *P < 0.05; **P < 0.01.
Fig. 4. The inﬂuence of Mstn on rat fat content. (A) Representative images of fat content in abdominal cavity of Mstn þ/þ and Mstn / rats. (B) Representative images collected by
MRI for determination of fat content in 5-month-old male rats. (C) Statistical analysis of MRI results. N ¼ 3. ****P < 0.0001.
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with the results obtained from examples of Mstn-mutant cattle
[45], humans [17,45], or Mstn-knockout mice [21,22] likely due to
Mstn decreasing adipogenesis in vivo [20,21]. To Mstn-knockout
mice the results were inconsonant though we accept the conclu-
sion that fat contents is reduction B In Mstn knockout mice fat
contents was not differences by the age of 11e14-week-old [2] until
by 5~6-month-old [22] than in WT mice, while in another paper a
signiﬁcant differences was observed by the age of 12-week-old
than that of WT mice [21]. Recently, Mstn knockout mice with a
high-fat diet revealed a large increase in visceral fat contents than
with normal diet, which is incompatible with Mstn knockout pro-
tecting against diet induced obesity in mice [41]. Therefore, further
researchs are needed to explore the mechnism of Mstn affection on
fat metabolism.
Currently, Mstn is being explored as a target to ameliorate
muscular dystrophy or muscle atrophy initiated bymultiple factors.
Development of Mstn-related molecules or manipulation of
endogenous Mstn levels also represent new potential strategies for
preventing or treating metabolic diseases such as muscle wasting,
obesity, and type 2 diabetes. The establishment of a rat Mstn
knockout model that more closely mirrors human physiology will
hopefully provide a valuable resource for future investigations into
Mstn function.
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